Aliases:This biomarker is also known as:
- polycomb protein EED,
- WD protein associating with integrin cytoplasmic tails 1,
- embryonic ectoderm development,
EED is a member of the Polycomb-group (PcG) family. PcG family members form multimeric protein complexes, which are involved in maintaining the transcriptional repressive state of genes over successive cell generations. EED is part of the PRC2/EED-EZH2 complex, which methylates 'Lys-9' and 'Lys-27' of histone H3, leading to transcriptional repression of the affected target gene. Genes repressed by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1 and CDKN2A. There are two known isoforms arising from two distinct transcript variants for this gene.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
No additional breast data available.
EED was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
- Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.
- Development and validation of sandwich ELISA microarrays with minimal assay interference.
- Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.